There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Eiger Biopharmaceuticals (EIGR – Research Report) and Atossa Therapeutics (ATOS – Research Report) with bullish sentiments.
Eiger Biopharmaceuticals (EIGR)
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Eiger Biopharmaceuticals, with a price target of $1.00. The company’s shares closed last Tuesday at $0.55, close to its 52-week low of $0.53.
According to TipRanks.com, Higgins is a 3-star analyst with an average return of
Currently, the analyst consensus on Eiger Biopharmaceuticals is a Moderate Buy with an average price target of $3.00.
See the top stocks recommended by analysts >>
Atossa Therapeutics (ATOS)
In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Atossa Therapeutics, with a price target of $4.00. The company’s shares closed last Tuesday at $0.87.
According to TipRanks.com, McCarthy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Atossa Therapeutics is a Moderate Buy with an average price target of $4.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EIGR:
